Listed by the USPTO as KNIGHT, TERESA E
Tech Center 1600 • Art Units: 1631 1632 1634 1657
This examiner grants 66% of resolved cases
KNIGHT, TERESA E works in tech center 1600 and art unit 1631. Her record contains 496 resolved cases, an allowance rate of 66.1%, and a median of 1247 days to allowance. The allowance rate indicates that a substantial share of resolved matters reached allowance, while the median timing reflects extended prosecution duration.
The interview lift is 48.1%, so interviews are associated with a meaningful improvement in outcomes in this record. Applicants may benefit from preparing focused interview agendas alongside written responses. The profile includes work involving the Board of Regents of the University of Texas System, University of Florida Research Foundation Inc., and Regeneron Pharmaceuticals Inc. The listed firms are pH IP Law, WOLF GREENFIELD & SACKS, P.C., and BakerHostetler.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18288301 | SYNTHETIC AAV VECTORS FOR REPEATED DELIVERY OF THERAPEUTIC GENES | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18918283 | RAPID PURIFICATION OF MONOCLONAL ANTIBODY FROM IN-PROCESS UPSTREAM CELL CULTURE MATERIAL | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18789888 | BIOCHEMICAL AND BIOMECHANICAL CONDITIONING FOR ENHANCING PERSONALIZED MESENCHYMAL STEM CELL THERAPIES | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18559460 | METHODS AND COMPOSITIONS FOR TRANSPORT, STORAGE, AND DELIVERY OF ADENO-ASSOCIATED VIRAL VECTOR AND OTHER MOLECULES | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18667505 | SCAFFOLDING MATERIAL FOR STEM CELL CULTURES AND STEM CELL CULTURE METHOD USING SAME | Non-Final OA | SEKISUI CHEMICAL CO., LTD. |
| 18568457 | METHODS OF EUKARYOTIC GENE EXPRESSION | Non-Final OA | CAMBRIDGE ENTERPRISE LIMITED |
| 18411654 | SYSTEMS AND METHODS FOR PRODUCING MICRO-ENGINEERED MODELS OF THE HUMAN CERVIX | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18964753 | SOFT TISSUE PROTEIN COMPOSITIONS, METHODS OF MAKING, AND USES THEREOF | Non-Final OA | Advanced Biologics, LLC |
| 18947876 | AMNIOTIC FLUID CELL-DERIVED EXTRACELLULAR MATRIX AND USES THEREOF | Non-Final OA | STEMBIOSYS, INC. |
| 18936806 | MESENCHYMAL STEM CELLS EXPRESSING CD146 RECEPTORS | Non-Final OA | Cell Technologies, Inc. |
| 18923157 | EX VIVO SUBCUTANEOUS INJECTION MODEL | Non-Final OA | GENOSKIN |
| 18545891 | PERMEATION OF WHOLE VERTEBRAL BODIES WITH A CRYOPROTECTANT USING VACUUM ASSISTED DIFFUSION | Non-Final OA | Ossium Health, Inc. |
| 18817206 | MITOCHONDRIAL AUGMENTATION THERAPY WITH STEM CELLS ENRICHED WITH FUNCTIONAL MITOCHONDRIA | Non-Final OA | Minovia Therapeutics Ltd. |
| 18269930 | METHOD FOR ISOLATING EXOSOMES WITH HIGH EFFICIENCY AND HIGH PURITY | Non-Final OA | UNION KOREA LIFE SCIENCES INC. |
| 18342896 | SELECTION AND USE OF UMBILICAL CORD CELL FRACTIONS SUITABLE FOR TRANSPLANTATION | Non-Final OA | Gamida Cell Ltd |
| 18599002 | STROMAL STEM CELLS | Non-Final OA | Orbsen Therapeutics Limited |
| 18687833 | METHODS AND SYSTEMS FOR ADIPOCYTES DIFFERENTIATION | Non-Final OA | The IP Law Firm of Guy Levi, LLC |
| 17623250 | COMPOSITION AND METHOD FOR RENDERING BIOLOGICAL MATERIAL | Non-Final OA | JELLOX BIOTECH INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy66.1% of resolved applications examined by Teresa E Knight were allowed (496 resolved cases), compared with 28.4% across Art Unit 1631 over the last five years.
This examiner's interview lift is +48.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Teresa E Knight took 1,247 days on average from filing to allowance.
Teresa E Knight examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
